Skyhawk Therapeutics anuncia los resultados finales de 15 meses del ensayo clínico de fase 1/2 de SKY-0515

Phase 1SKY-0515Neutral

AI Analysis

Summary

Skyhawk Therapeutics announced 15-month final results from its Phase 1/2 clinical trial of SKY-0515 in Huntington's disease patients. The dataset represents the final analysis of the Phase 1/2 study at the 15-month evaluation point.

Clinical Trial Data

Phase

1/2

Outcome Details

15-month final results from Phase 1/2 clinical trial

Importance:5/10

Sentiment:

0.00

clinical trialPhase 1/2Huntington's diseaseSKY-0515final results

Read the original article

Published by PR Newswire Biotech on September 16, 2026 10:27 AM

Read Original